Ka-ching! That’s the sound of the government’s cash register after the first tax bill from the Affordable Care Act’s medical device tax hit the industry for $97 million this week, according to trade groups.
Medical device companies are grumbling, but investors have yet to feel the hit. It could only be a matter of time, however — and this earnings season has already given us a glimpse of what companies are doing to adapt.
Taxes, job cuts, and an industry in transition
Industry groups estimate the tax — put in place in order to help pay for the sweeping reforms of the Affordable Care Act — will drain $194 million per month from the industry en route to coughing up around $29 billion over the next 10 years. That’s chump change for the biggest players in the business, but for the smaller or financially challenged companies in the industry struggling to compete, the 2.3% hit on sales has already forced some changes.
Boston Scientific Corporation (NYSE:BSX) is unloading a new round of layoffs despite recording a better-than-expected fourth quarter. Company CEO Michael Mahoney announced up to 1,000 job cuts after the earnings release, citing the tax’s hit — along with slow growth in some of the company’s units — as a factor in the move.
With Mahoney predicting a tax blow of $75 million to Boston Sci, layoffs are the least he can do to keep the company’s finances afloat, particularly with the cardiac rhythm management and interventional cardiology units — Boston Scientific’s two largest divisions — continuing to see sales fall.
A turn for the worse
Suffice to say, I don’t think the government had these sorts of job cuts in mind when it announced the tax. Zimmer Holdings, Inc. (NYSE:ZMH) already beat Boston Sci to the punch, cutting 450 jobs last year partly because of fear over the tax’s hit. Zimmer’s flat sales and slight drop in profit in its recent quarterly report have pushed the company to announce that it will continue to streamline operations, so more job cuts could be coming.
Medtronic, Inc. (NYSE:MDT)‘s also in the midst of a job-cutting program, with 500 positions slashed and another 500 to come as the company predicts losses of up to $175 million annually.
So, what can you expect going forward? Job cuts and other operational changes should continue to hit smaller or less prominent companies, such as Boston Sci and Zimmer. Even large companies could be forced to change their plans, particularly those with lower growth projections – such as the new Abbott Laboratories (NYSE:ABT), which finds itself much more exposed to the medical device industry after its spinoff. The company’s already promised job cuts due to the tax, and more operational maneuvering wouldn’t be surprising. Abbott’s better positioned than most, with a portfolio that stretches well beyond the United States and into generic drugs and other products, but don’t expect the company to come away without a scratch from the tax.